CINV Existing and Pipeline Drugs Market

CINV Existing and Pipeline Drugs Market (Major Drug: Aloxi, Zofran Generic, Kytril Generic, Emend, Akynzeo, SUSTOL, and Rolapitant) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

CINV Existing and Pipeline Drugs Market Outlook 2031

  • The global CINV existing and pipeline drugs market was valued at US$ 1.9 Bn in 2021
  • It is estimated to grow at a CAGR of 5.8% from 2022 to 2031
  • The global CINV existing and pipeline drugs market is expected to surpass value of US$ 3.2 Bn by the end of 2031

Analysts’ Viewpoint on Global CINV Existing and Pipeline Drugs Market Scenario

Large number of ongoing research & development activities, increasing healthcare investment by government, and rising geriatric population suffering from cancer are some of the factors driving the global CINV existing and pipeline drugs market. Companies in the global CINV existing and pipeline drugs market are focused on the development of novel drugs to offer better treatment to patients. However, dearth of awareness among people about the availability of effective drugs and treatments is expected to hamper the growth of the global CINV existing and pipeline drugs market during the forecast period.

cinv existing and pipeline drugs market

Overview of Global CINV Existing and Pipeline Drugs Market

Chemotherapy-induced nausea and vomiting (CINV) refers to nausea and vomiting associated with cancer chemotherapy. CINV is one of the most common side effects experienced by cancer patients undergoing chemotherapy. Presently, several drugs are available to manage CINV; however, side effects continue to be a key concern for patients and oncologists associated with chemotherapy. Companies such as Helsinn Holding S.A., Heron Therapeutics, Inc., and Tesaro, Inc. are striving to develop new and more efficacious therapeutic solutions to treat CINV.

Request a sample to get extensive insights into the CINV Existing and Pipeline Drugs Market

Increase in Incidence Rate of Various Types of Cancer

The world is witnessing a continuous increase in the incidence rate of various types of cancer, which results in rise in the number of patients undergoing chemotherapy. According to estimates from the World Health Organization (WHO) in 2019, cancer is the first or second leading cause of death before the age of 70 years in 112 of 183 countries, and ranks third or fourth in a further 23 countries. These facts indicate that increase in cases of various types of cancer is likely to induce oncologists to prescribe chemotherapy to their patients for the effective treatment of cancer, thereby driving the CINV existing and pipeline drugs market.

Generally, 25% to 30% patients with cancer receive chemotherapy as a treatment option, and 70% to 80% of these patients undergoing chemotherapy exhibit nausea and vomiting as major symptoms.

Companies Undertaking R&D Activities to Develop Advanced Drugs

Significant rise in cancer research and development efforts and increase in attention on the development of novel therapies are expected to drive the global CINV existing and pipeline drugs market over the next few years. Additionally, the introduction of new pharmaceuticals and the rapid growth of the healthcare industry are expected to propel the market in the near future. However, consumers' lack of information regarding the availability of innovative and effective pharmaceuticals and treatments is projected to impact the growth of the market in the next years.

Request a custom report on CINV Existing and Pipeline Drugs Market

SUSTOL (APF-530) Segment to Dominate Global Market

SUSTOL (APF-530) was launched in 2015. The approval of SUSTOL drugs is likely to drive the global market during the forecast period. Increase in the number of patients undergoing chemotherapy is expected to contribute to the growth of the global CINV existing and pipeline drugs market. Various sources indicate that 70% to 80% cancer patients on chemotherapy exhibit nausea and vomiting as major side effects.

Rolapitant to Witness Demand Due to Ability to Suppress Vomiting

Rolapitant was approved in 2015. Since then, the demand for the drug has increased among various countries. Pipeline drugs have shown better efficacy than existing drugs during the clinical study. Rolapitant is used with other drugs to delay nausea and vomiting caused by cancer drug treatment (chemotherapy). It acts by suppressing one of the body's natural chemicals (substance P/neurokinin 1) that produces vomiting. Therefore, the launch of these more efficacious drugs is likely to encourage physicians to prescribe these new drugs over existing drugs

Regional Outlook of Global CINV Existing and Pipeline Drugs Market

The global CINV existing and pipeline drugs market has been segmented into North America, Europe, Asia Pacific Latin America, and Middle East & Africa. North America was the largest market for CINV drugs in 2021, accounting for over 45% share. The region is expected to retain its leadership position during the forecast period. The market in North America is likely to expand at a CAGR of over 7% from 2022 to 2031.

Europe was the second largest market for CINV drugs in 2021. The launch of CINV pipeline drugs in Europe is projected to be a year later than in North America, given the delays on the past launches of CINV drugs such as Aloxi and Emend.

The CINV existing and pipeline drugs market in Asia Pacific is driven by increase in penetration of western companies and rise in the number of cancer patients. Generic manufacturers in countries in Asia Pacific and emerging regions compete with the branded CINV drug manufacturers. The demand for generic versions of expired branded drugs is high in the region due to low purchasing power of the people. Strong economic growth in countries such as India and China and improving healthcare infrastructure are anticipated to drive the CINV existing and pipeline drugs market in Asia Pacific.

Analysis of Key Players in Global CINV Existing and Pipeline Drugs Market

Key players operating in the global CINV existing and pipeline drugs market include GlaxoSmithKline plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc., and Tesaro, Inc. Each of these players has been profiled in the global CINV existing and pipeline drugs market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments.

Key Developments in Global CINV Existing and Pipeline Drugs Market

  • In October 2020, Tetra Bio-Pharma has unveiled its commercial vision on a Robust chemotherapy induced nausea & vomiting portfolio. Company has the strategy to bring the innovative therapies to patients suffering from chemotherapy-induced nausea & vomiting.
  • In July 2019, Nuformix, the pharmaceutical development company used cocrystal technology and commenced the clinical studies for NXP001
  • In July 2018, Glenmark Pharmaceuticals, one of the global leading companies in the pharmaceuticals, launched drug Akynzeo for chemotherapy-induced nausea in India and Nepal. Akynzeo is the combination of netupitant and palonosetron.

Global CINV Existing and Pipeline Drugs Market Snapshot

Attribute

Detail

Market Size Value in 2021 (Base Year)

US$ 1.9 Bn

Market Forecast Value in 2031

US$ 3.2 Bn

Growth Rate (CAGR)

5.8%

Forecast Period

2022–2031

Quantitative Units

US$ Mn for Value

Market Analysis

It includes cross segment analysis at regional level. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, pricing analysis, and parent industry overview.

Format

Electronic (PDF)

Market Segmentation

  • Major Drug
    • Aloxi (Palonosetron)
    • Zofran Generic (Ondansetron)
    • Kytril Generic (Granisetron)
    • Emend (Aprepitant)
    • Akynzeo (Netupitant-Palonosetron)
    • SUSTOL (Extended Release Granisetron Injection)
    • Rolapitant

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
  • China
  • India
  • Japan
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Brazil
  • Mexico
  • Rest of Latin America
  • GCC Countries
  • South Africa
  • Rest of MEA

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global CINV existing and pipeline drugs market in 2021?

The global CINV existing and pipeline drugs market was valued at US$ 1.9 Bn in 2021

How big will be the global CINV existing and pipeline drugs market in 2031?

The global CINV existing and pipeline drugs market is projected to exceed US$ 3.2 Bn by 2031

What will be the CAGR of the global existing and pipeline drugs market during the forecast period (2022–2031)?

The global CINV existing and pipeline drugs market is anticipated to grow at a CAGR of 5.8% during forecast period

What is the market share of leading segment of the global existing and pipeline drugs market?

The rolapitant segment accounted for nearly 61% share of the global CINV existing and pipeline drugs market in 2021

Which region will capture the major market share during the forecast period?

North America is expected to account for the largest share of the global market during the forecast period

Who are the prominent players in global CINV existing and pipeline drugs market?

Prominent players in the global CINV existing and pipeline drugs market are GlaxoSmithKline plc, Helsinn Holding S.A., Heron Therapeutics, Inc., Merck & Co., Inc., and Tesaro, Inc.

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global CINV Existing and Pipeline Drugs Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Major Drugs Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1.Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global CINV Existing and Pipeline Drugs Market Analysis and Forecasts, 2017–2031

            4.4.1. Market Revenue Projections (US$ Mn)

            4.4.2. Market Volume/Unit Shipments Projections

        4.5. Porter’s Five Force Analysis

    5. Key Insights

        5.1. Installed Base Scenario (2019)

            5.1.1. Installed Base Scenario

                5.1.1.1. By Major Drugs

                5.1.1.2. By Region

                5.1.1.3. By Major Players

            5.1.2. New versus Replacement Unit Shipments

        5.2. Export-Import Scenario

            5.2.1. Export-Import Scenario, by Region*

        5.3. Price Comparison Analysis (2019)

            5.3.1. By Major Drugs Type

            5.3.2. By End User Type

            5.3.3. By Region

            5.3.4. By Major Players

        5.4. Key Potential Customers

            5.4.1. Key Potential Customers by Region

        5.5. Key Vendor and Distributor Analysis

            5.5.1. Key Vendor Analysis by Major Players

            5.5.2. Key Distributor Analysis by Major Players

        5.6. Technological Advancements

        5.7. Regulatory Scenario, by Region/globally

        5.8. Key Industry Events (mergers, acquisitions, partnerships, etc.)

        5.9. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)

    6. Global CINV Existing and Pipeline Drugs Market Analysis and Forecasts, By Major Drugs

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast, by Major Drugs, 2017–2031

            6.3.1. Aloxi (palonosetron)

            6.3.2. Zofran Generic (ondansetron)

            6.3.3. Kytril Generic (granisetron)

            6.3.4. Emend (aprepitant)

            6.3.5. Akynzeo (netupitant-palonosetron)

            6.3.6. SUSTOL (extended release granisetron injection)

            6.3.7. Rolapitant

        6.4. Market Attractiveness Analysis, By Major Drugs

    7. Global CINV Existing and Pipeline Drugs Market Analysis and Forecasts, By Region

        7.1. Key Findings

        7.2. Market Value Forecast, by Region

            7.2.1. North America

            7.2.2. Europe

            7.2.3. Asia Pacific

            7.2.4. Latin America

            7.2.5. Middle East & Africa

        7.3. Market Attractiveness Analysis, By Region

    8. North America  CINV Existing and Pipeline Drugs Market Analysis and Forecast

        8.1. Introduction

            8.1.1. Key Findings

        8.2. Market Value Forecast, by Major Drugs, 2017–2031

            8.2.1. Aloxi (palonosetron)

            8.2.2. Zofran Generic (ondansetron)

            8.2.3. Kytril Generic (granisetron)

            8.2.4. Emend (aprepitant)

            8.2.5. Akynzeo (netupitant-palonosetron)

            8.2.6. SUSTOL (extended release granisetron injection)

            8.2.7. Rolapitant

        8.3. Market Value Forecast, by Country, 2017–2031

            8.3.1. U.S.

            8.3.2. Canada

        8.4. Market Attractiveness Analysis

            8.4.1. By Major Drugs

            8.4.2. By Country

    9. Europe  CINV Existing and Pipeline Drugs Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Market Value Forecast, by Major Drugs, 2017–2031

            9.2.1. Aloxi (palonosetron)

            9.2.2. Zofran Generic (ondansetron)

            9.2.3. Kytril Generic (granisetron)

            9.2.4. Emend (aprepitant)

            9.2.5. Akynzeo (netupitant-palonosetron)

            9.2.6. SUSTOL (extended release granisetron injection)

            9.2.7. Rolapitant

        9.3. Market Value Forecast, by Country/Sub-region, 2017–2031

            9.3.1. Germany

            9.3.2. U.K.

            9.3.3. France

            9.3.4. Italy

            9.3.5. Spain

            9.3.6. Rest of Europe

        9.4. Market Attractiveness Analysis

            9.4.1. By Major Drugs

            9.4.2. By Country/Sub-region

    10. Asia Pacific CINV Existing and Pipeline Drugs Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Major Drugs, 2017–2031

            10.2.1. Aloxi (palonosetron)

            10.2.2. Zofran Generic (ondansetron)

            10.2.3. Kytril Generic (granisetron)

            10.2.4. Emend (aprepitant)

            10.2.5. Akynzeo (netupitant-palonosetron)

            10.2.6. SUSTOL (extended release granisetron injection)

            10.2.7. Rolapitant

        10.3. Market Value Forecast, by Country/Sub-region, 2017–2031

            10.3.1. Japan

            10.3.2. China

            10.3.3. India

            10.3.4. Australia & New Zealand

            10.3.5. Rest of Asia Pacific

        10.4. Market Attractiveness Analysis

            10.4.1. By Major Drugs

            10.4.2. By Country/Sub-region

    11. Latin America CINV Existing and Pipeline Drugs Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Major Drugs, 2017–2031

            11.2.1. Aloxi (palonosetron)

            11.2.2. Zofran Generic (ondansetron)

            11.2.3. Kytril Generic (granisetron)

            11.2.4. Emend (aprepitant)

            11.2.5. Akynzeo (netupitant-palonosetron)

            11.2.6. SUSTOL (extended release granisetron injection)

            11.2.7. Rolapitant

        11.3. Market Value Forecast, by Country/Sub-region, 2017–2031

            11.3.1. Brazil

            11.3.2. Mexico

            11.3.3. Rest of Latin America

        11.4. Market Attractiveness Analysis

            11.4.1. By Major Drugs

            11.4.2. By Country/Sub-region

    12. Middle East & Africa CINV Existing and Pipeline Drugs Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Major Drugs, 2017–2031

            12.2.1. Aloxi (palonosetron)

            12.2.2. Zofran Generic (ondansetron)

            12.2.3. Kytril Generic (granisetron)

            12.2.4. Emend (aprepitant)

            12.2.5. Akynzeo (netupitant-palonosetron)

            12.2.6. SUSTOL (extended release granisetron injection)

            12.2.7. Rolapitant

        12.3. Market Value Forecast, by Country/Sub-region, 2017–2031

            12.3.1. GCC Countries

            12.3.2. South Africa

            12.3.3. Rest of Middle East & Africa

        12.4. Market Attractiveness Analysis

            12.4.1. By Major Drugs

            12.4.2. By Country/Sub-region

    13. Competition Landscape

        13.1. GlaxoSmithKline plc

            13.1.1. Company Overview

            13.1.2. Financial Overview

            13.1.3. Product Portfolio

            13.1.4. Business Strategies

            13.1.5. Recent Developments

        13.2. Helsinn Holding S.A.

            13.2.1. Company Overview

            13.2.2. Financial Overview

            13.2.3. Product Portfolio

            13.2.4. Business Strategies

            13.2.5. Recent Developments

        13.3. Heron Therapeutics, Inc.

            13.3.1. Company Overview

            13.3.2. Financial Overview

            13.3.3. Product Portfolio

            13.3.4. Business Strategies

            13.3.5. Recent Developments

        13.4. Merck & Co., Inc.

            13.4.1. Company Overview

            13.4.2. Financial Overview

            13.4.3. Product Portfolio

            13.4.4. Business Strategies

            13.4.5. Recent Developments

        13.5. Tesaro, Inc.

            13.5.1. Company Overview

            13.5.2. Financial Overview

            13.5.3. Product Portfolio

            13.5.4. Business Strategies

            13.5.5. Recent Developments

    List of Tables

    Table 1: List of Abbreviations

    Table 2: Market Snapshot: Global CINV Existing and Pipeline Drugs Market (2021 & 2031)

    Table 3: Chemotherapy Induced Nausea and Vomiting (CINV): Subtypes and Description

    Table 4: Treatment Recommendations for CINV

    Table 5: Event Impact Analysis: Global CINV Drugs Market

    Table 6: Global CINV Drugs Market Revenue, by Major Drugs, 2017 - 2031

    Table 7: Global CINV Estimated Patient Pool, by Major Drugs, 2017 - 2031 (Thousands)

    Table 8: SWOT Analysis for SUSTOL

    Table 9: Efficacy of SUSTOL with Difficult Chemo Regimens

    Table 10: SWOT Analysis for Rolapitant

    Table 11: Overview of Rolapitant Efficacy Analysis

    Table 12: Global CINV Drugs Market Revenue, by Region, 2017 - 2031

    Table 13: Global CINV Estimated Patient Pool, by Geography, 2017 - 2031 (Thousands)

    Table 14: North America CINV Pipeline Drugs Market Revenue, 2017 - 2021

    Table 15: North America CINV Estimated Patient Pool, by Pipeline Drug, 2017 - 2021 (Thousands)

    Table 16: Europe CINV Pipeline Drugs Market Revenue, 2022 – 2031

    Table 17: Europe CINV Estimated Patient Pool, by Pipeline Drug, 2022 – 2031 (Thousands)

    Table 18: GlaxoSmithKline plc: Expenses & Revenue, 2011 – 2017

    Table 19: Helsinn Holding S.A.: Pipeline Product Portfolio

    Table 20: Heron Therapeutics, Inc.: Expenses & Revenue, 2011 – 2017

    Table 21: Heron Therapeutics, Inc.: Pipeline Product Portfolio

    Table 22: Merck & Co., Inc.: Expenses & Revenue, 2011 – 2017

    Table 23: Tesaro, Inc.: Expenses & Revenue, 2011 – 2017

    Table 24: Tesaro, Inc.: Pipeline Product Portfolio

    List of Figures

    Figure 1: CINV Existing and Pipeline Drugs: Market Segmentation

    Figure 2: Global CINV Drugs Market (US$ Mn), by Major Drugs, 2021

    Figure 3: Comparative Analysis: Global CINV Drugs Market Revenue, by Geography, 2017 & 2031 (Value %)

    Figure 4: Pathogenesis of CINV

    Figure 5: Unmet Needs in the CINV Market

    Figure 6: Comparative Analysis: Global CINV Drugs Market Revenue, by Major Drugs, 2017 & 2031 (Value %)

    Figure 7: Global Aloxi Market Revenue, 2017 - 2031

    Figure 8: Global Zofran Generic Market Revenue, 2017 - 2031

    Figure 9: Global Kytril Generic Market Revenue, 2017 - 2031

    Figure 10: Global Emend Market Revenue, 2017 - 2031

    Figure 11: Global Akynzeo Market Revenue, 2017 - 2021

    Figure 12: Global SUSTOL Market Revenue, 2022 – 2031

    Figure 13: Primary Efficacy Results: Complete Response with Patients Receiving MEC

    Figure 14: Primary Efficacy Results: Complete Response with Patients Receiving HEC

    Figure 15: Global Rolapitant Market Revenue, 2017 - 2021

    Figure 16: North America CINV Drugs Market Revenue, 2017 - 2031

    Figure 17: Europe CINV Drugs Market Revenue, 2017 - 2031

    Figure 18: Asia Pacific CINV Drugs Market Revenue, 2017 - 2031

    Figure 19: Latin America CINV Drugs Market Revenue, 2017 - 2031

    Figure 20: Middle East & Africa CINV Drugs Market Revenue, 2017 - 2031

Copyright © Transparency Market Research, Inc. All Rights reserved